March 2020 FIRST PROSTATE CANCER THERAPY TO TARGET GENES DELAYS CANCER PROGRESSIONFeaturing: Maha Hussain, MBChB
Episode SummaryFor the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, according to a large, international phase 3 trial. Maha Hussain, MD, Deputy Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University was one of the principal investigators of the PROfound trial is from Northwestern Medicine.
|
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|